Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

3S Bio Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

3SBio Inc. Received Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212

Details:

Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.

Lead Product(s): Pegadricase

Therapeutic Area: Musculoskeletal Product Name: SEL-212

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Selecta Biosciences

Deal Size: $4.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY